
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2010

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California

001-14758

33-0476164

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(I.R.S. Employer
Identification No.)

3260 Whipple Road, Union City, California
(Address of Principal Executive Offices)

94587
(Zip Code)

Registrant's telephone number, including area code: **(510) 400-0700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 28, 2010, Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), held its annual meeting of shareholders. The Company solicited proxies for the meeting pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended. As of the April 1, 2010 record date for the annual meeting, there were 62,040,454 shares of the Company’s common stock outstanding.

The Company’s nominees for election to its board of directors as listed in the Company’s proxy statement were each elected to a one-year term, with the results of the voting as follows:

| Nominee | Votes For | Votes Withheld | Broker Non-Votes |
|--------------------|------------------|-----------------------|-------------------------|
| Don M. Bailey | 41,822,326 | 585,457 | 8,596,592 |
| Neal C. Bradsher | 41,589,281 | 818,502 | 8,596,592 |
| Stephen C. Farrell | 42,070,629 | 337,154 | 8,596,592 |
| Louis Silverman | 42,061,050 | 346,733 | 8,596,592 |
| Virgil D. Thompson | 41,467,283 | 940,500 | 8,596,592 |

The Company also requested shareholder ratification of the selection of Odenberg, Ullakko, Muranishi & Co. LLP (“OUM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010. As indicated below, the proposal to ratify the appointment of OUM was approved:

| Description | Votes For | Votes Against | Abstain |
|------------------------------------|------------------|----------------------|----------------|
| Ratification of Appointment of OUM | 49,913,185 | 1,062,352 | 28,838 |

As indicated in the above table, the proposal to ratify the appointment of OUM was approved.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2010

QUESTCOR PHARMACEUTICALS, INC.

By: /s/ Gary M. Sawka
Gary M. Sawka
Senior Vice President, Finance and Chief Financial Officer